Skip to main content

Table 4 Echocardiographic parameters at baseline and follow-up (n = 21)

From: Sacubitril/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: real-world data

 

Baseline

Follow-up

P

LA volume (ml/m2)

48.3 ± 19.6

34.3 ± 23.1

0.050

LVED volume (ml/ m2)

87.1 ± 31.7

66.8 ± 37.2

0.002

LV- EF (%)

26.8 ± 5.4

39.2 ± 10.0

0.0004

LV-GLS (-%)

8.1 ± 2.9

12.4 ± 3.8

0.001

Septal wall thickness (IVS, mm)

10.8 ± 1.8

10.9 ± 2.0

0.756

sPAP (mmHg)

46.5 ± 11.5

40.4 ± 18.2

0.156

RV TAPSE (mm)

16.4 ± 2.6

18.8 ± 2.6

0.0006

RV TDI (m/s)

0.093 ± 0.02

0.101 ± 0.02

0.009

Normal RV function, (n, %)

7 (33.3)

9 (42.9)

 

LV diastolic function

 Grade I n (%)

1 (4.7)

5 (23.8)

 

 Grade II, n (%)

6 (28.6)

2 (9.5)

 

 Grade III, n (%)

5 (23.8)

-

 

Tricuspid regurgitation (grade)

1.6 ± 0.8

1.4 ± 0.9

0.227

Mitral Rrgurgitation (grade)

2.0 ± 0.8

1.5 ± 0.5

0.008

  1. Abbreviations: LA Left atrium, LVED Left ventricle end diastolic, LV- EF Left ventricular ejection fraction, LV-GLS Left ventricular global longitudinal strain, LVF Left ventricular function, IVS Intraventricular septum, sPAP Systolic pulmonary artery pressure, TAPSE Tricuspid anular plane systolic excursion, RV TDI Right ventricular tissue doppler imaging